EUROPEAN COMMISSION APPROVES AMGEN’S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
L'Unione Europea ha approvato il farmaco IMDYLLTRA® per il trattamento del cancro ai polmoni a piccole cellule in stadio esteso. La decisione si basa sui risultati di uno studio di fase 3, che ha mostrato una riduzione del 40% del rischio di morte rispetto alla chemioterapia. Il medicinale rappresenta una nuova opzione terapeutica per pazienti con malattia in progressione. La decisione è stata comunicata da un'azienda farmaceutica.
COMUNICATO STAMPA – CONTENUTO PROMOZIONALE Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to Chemotherapy Novel Treatment Option for Patients with Extensive-Stage Small Cell Lung Cancer That Has Progressed THOUSAND OAKS, Calif., June 1, 2026 PRNewswire — Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy. 🔗 Leggi su Corrieretoscano.it
Notizie e thread social correlati
PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell FailurePeproMene Bio ha annunciato che presenterà i risultati di uno studio sulla sua terapia con cellule T CAR BAFF-R, chiamata PMB-CT01, durante l’EHA...
Intertribal Timber Council Responds to European Commission EUDR Review: “No Relief for Indigenous Forest Stewardship”Il Consiglio Intertribale del settore forestale ha risposto alla revisione dell’European Union Deforestation Regulation (EUDR) della Commissione...
EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCERApproval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDYLLTRA Compared to Chemotherapy ... adnkronos.com
EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVISFirst and Only CD19-Targeted Therapy Approved in Europe for Adults with anti-AChR+ and anti-MuSK+ gMG UPLIZNA Demonstrates Durable Disease Control with Twice-Yearly Dosing* THOUSAND OAKS, Calif., Feb. adnkronos.com
➜